As we previously reported, earlier this year Merck announced that it would be spinning off its women’s health, biosimilars, and established brands businesses into a standalone company. This month, Merck completed the spinoff, creating Organon. Organon’s portfolio contains about 60 treatments and products, and mainly focuses on ex-US markets. Organon also plans to acquire Alydia Health, which focuses on prevention of maternal morbidity and mortality caused by abnormal postpartum bleeding, as part of its focus on women’s health treatments